Overview
NBIX market data
Price History
NBIX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for NBIX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200Benzinga · Jul 21, 2026, 1:49 PM
Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200Benzinga · Jul 17, 2026, 2:25 PM
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200Benzinga · Jul 13, 2026, 4:26 PM
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $170Benzinga · Jul 13, 2026, 12:59 PM
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $195Benzinga · Jul 7, 2026, 3:50 PM
Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal HyperplasiaBenzinga · Jul 1, 2026, 8:15 PM
Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWSBenzinga · Jun 15, 2026, 8:20 PM
Neurocrine Biosciences Presents New Two-Year Data From Phase 3 CAHtalyst Pediatric Trial Of CRENESSITY At Endocrine Society's Annual MeetingBenzinga · Jun 15, 2026, 12:45 PM
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New BuysBenzinga · Jun 10, 2026, 9:15 PM
Neurocrine Biosciences Reports Rapid Tardive Dyskinesia Improvement With INGREZZA In Patients With Intellectual And Developmental DisabilitiesBenzinga · Jun 8, 2026, 12:45 PM